Organogenesis Holdings (2PQ) Stock Price & Analysis
2PQ Stock Chart & Stats
- Day’s Range
- EUR 0.68 - EUR 0.73
- 52-Week Range
- EUR 0.68 - EUR 5.75
- Previous Close
- EUR 0.73
- Volume
- N/A
- Average Volume (3M)
- 0
- Market Cap
- EUR 88.50M
- Enterprise Value
- EUR 472.65M
- Total Cash (Recent Filing)
- EUR 46.10M
- Total Debt (Recent Filing)
- EUR 66.95M
- Price to Earnings (P/E)
- ―
- Beta
- 0.75
- Next Earnings
- Nov 05, 2026 (Est.)
- EPS Estimate
- -0.16
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Cash Generation
Positive operating and free cash flow provide internal funding capacity despite the reported net loss. If maintained, this cash generation can support operations, reduce reliance on external financing, and give management flexibility while the business works through its recovery and cost restructuring.
Regulatory And Clinical Progress
FDA acceptance advances Amnuvx into a defined regulatory review process and creates a potential future growth platform in symptomatic knee osteoarthritis. Approval is not assured, but the milestone strengthens the pipeline and could broaden Organogenesis beyond its current wound-care base.
Structural Cost Reduction
The restructuring program is substantial relative to the company’s cost base and should improve operating leverage if revenue stabilizes. Workforce and expense reductions can extend liquidity, narrow future losses, and create a leaner platform for rebuilding profitability once demand recovers.
Bears Say
Severe Revenue Decline
The sharply reduced outlook indicates that the current demand and market reset is more severe than previously expected. Such a large revenue contraction threatens scale, weakens fixed-cost absorption, and makes a durable return to profitability dependent on successful recovery in core product volumes.
Margin And Profitability Pressure
Material gross-margin compression combined with widening operating and net losses shows that the earnings reset is not limited to slower sales. Lower profitability reduces the cash produced per product sold, raises the revenue needed to break even, and may constrain investment in future growth.
Liquidity And Financing Sensitivity
The halving of cash over six months increases dependence on operating improvement and potential external funding. An ATM facility provides flexibility, but issuing equity can dilute existing holders and signals that liquidity remains sensitive to continued losses, delayed launches, and slower-than-expected recovery.
Organogenesis Holdings News
2PQ FAQ
What was Organogenesis Holdings’s price range in the past 12 months?
What is Organogenesis Holdings’s market cap?
When is Organogenesis Holdings’s upcoming earnings report date?
How were Organogenesis Holdings’s earnings last quarter?
Is Organogenesis Holdings overvalued?
Does Organogenesis Holdings pay dividends?
What is Organogenesis Holdings’s EPS estimate?
How many shares outstanding does Organogenesis Holdings have?
What happened to Organogenesis Holdings’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Organogenesis Holdings?
What is the TipRanks Smart Score and how is it calculated?
Organogenesis Holdings Stock Smart Score
Company Description
Organogenesis Holdings
Organogenesis Holdings Inc. is a U.S.-based regenerative medicine firm that specializes in creating, producing, and marketing innovative therapies for advanced wound management, as well as surgical and sports medicine applications. Within its advanced wound care portfolio, Organogenesis offers several distinct products. These include Affinity and Novachor, both amniotic membrane dressings designed to preserve vital cells, growth factors, and ECM proteins found in natural tissue. Apligraf is a bioengineered living cell therapy that releases a range of healing cytokines and growth factors, while Dermagraft is another bioengineered solution that generates human collagen, ECM, proteins, and cytokines. NuShield provides a wound covering incorporating both amnion and chorion membranes to maintain a spongy intermediate layer. PuraPly acts as an antimicrobial barrier, allowing for flexibility and effective fluid drainage. For the surgical and sports medicine sectors, the company provides products such as NuCel, a dehydrated placental tissue designed for surgical application to promote natural tissue regeneration. ReNu is a cryopreserved suspension aimed at aiding soft tissue recovery. Additionally, FiberOS and OCMP serve as bone void fillers, primarily utilized in orthopedic and neurosurgical procedures. Looking ahead, Organogenesis's product pipeline features PuraPly XT and PuraPly MZ, which are being developed for treating chronic, acute, and open wounds. PuraForce is a bioengineered porcine collagen surgical matrix intended for soft tissue reinforcement. TransCyte, another bioengineered tissue, is in development for addressing partial thickness burns. Organogenesis distributes its offerings to a diverse client base, including hospitals, specialized wound care centers, government institutions, ambulatory surgical centers, and physician offices, leveraging both its direct sales team and independent agencies. Established in 1985, the company maintains its headquarters in Canton, Massachusetts.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Gary S. Gillheeney
- Employees
- 854
- Website
- organogenesis.com
- Address
- 85 Dan Road, Canton, MA, 02021, US
Organogenesis Holdings (2PQ) Earnings & Revenues
2PQ Earnings Call
Earnings Call SentimentNegative
The call presented meaningful operational and clinical positives — sequential revenue recovery, strong clinical trial results (PuraPly AM and Affinity), FDA acceptance of the Amnuvx BLA and tangible cost-reduction measures — but these are outweighed by significant near-term financial stress: severe year-over-year revenue declines (≈58%), large operating and GAAP net losses, a halved cash position since year-end, lowered full-year revenue guidance, and deferred product launch timing to preserve cash. Management is focused on evidence-driven market share gains and expects improving adjusted EBITDA by Q4, but the company remains in a substantial recovery phase with execution and financing risks in the near term.
View all DE:2PQ earnings summaries2PQ Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 6 | 0 | 16 |
| Technical Analysis | 6 | 0 | 4 |
| Moving Averages | 0 | 0 | 12 |
